334 related articles for article (PubMed ID: 20610624)
41. MicroRNA-375 is downregulated in gastric carcinomas and regulates cell survival by targeting PDK1 and 14-3-3zeta.
Tsukamoto Y; Nakada C; Noguchi T; Tanigawa M; Nguyen LT; Uchida T; Hijiya N; Matsuura K; Fujioka T; Seto M; Moriyama M
Cancer Res; 2010 Mar; 70(6):2339-49. PubMed ID: 20215506
[TBL] [Abstract][Full Text] [Related]
42. Targeted degradation of KRAS by an engineered ubiquitin ligase suppresses pancreatic cancer cell growth in vitro and in vivo.
Ma Y; Gu Y; Zhang Q; Han Y; Yu S; Lu Z; Chen J
Mol Cancer Ther; 2013 Mar; 12(3):286-94. PubMed ID: 23288781
[TBL] [Abstract][Full Text] [Related]
43. GSK-3α promotes oncogenic KRAS function in pancreatic cancer via TAK1-TAB stabilization and regulation of noncanonical NF-κB.
Bang D; Wilson W; Ryan M; Yeh JJ; Baldwin AS
Cancer Discov; 2013 Jun; 3(6):690-703. PubMed ID: 23547054
[TBL] [Abstract][Full Text] [Related]
44. Aberrant microRNA expression likely controls RAS oncogene activation during malignant transformation of human prostate epithelial and stem cells by arsenic.
Ngalame NN; Tokar EJ; Person RJ; Xu Y; Waalkes MP
Toxicol Sci; 2014 Apr; 138(2):268-77. PubMed ID: 24431212
[TBL] [Abstract][Full Text] [Related]
45. [Kras oncogene and pancreatic cancer: thirty years after].
Bournet B; Dufresne M; Selves J; Torrisani J; Cordelier P; Buscail L
Med Sci (Paris); 2013 Nov; 29(11):991-7. PubMed ID: 24280502
[TBL] [Abstract][Full Text] [Related]
46. KRAS in pancreatic cancer.
Agarwal A; Saif MW
JOP; 2014 Jul; 15(4):303-5. PubMed ID: 25076326
[TBL] [Abstract][Full Text] [Related]
47. Oncogenic KRAS induces progenitor cell expansion and malignant transformation in zebrafish exocrine pancreas.
Park SW; Davison JM; Rhee J; Hruban RH; Maitra A; Leach SD
Gastroenterology; 2008 Jun; 134(7):2080-90. PubMed ID: 18549880
[TBL] [Abstract][Full Text] [Related]
48. RAGE is essential for oncogenic KRAS-mediated hypoxic signaling in pancreatic cancer.
Kang R; Hou W; Zhang Q; Chen R; Lee YJ; Bartlett DL; Lotze MT; Tang D; Zeh HJ
Cell Death Dis; 2014 Oct; 5(10):e1480. PubMed ID: 25341034
[TBL] [Abstract][Full Text] [Related]
49. KRAS mutational subtype and copy number predict in vitro response of human pancreatic cancer cell lines to MEK inhibition.
Hamidi H; Lu M; Chau K; Anderson L; Fejzo M; Ginther C; Linnartz R; Zubel A; Slamon DJ; Finn RS
Br J Cancer; 2014 Oct; 111(9):1788-801. PubMed ID: 25167228
[TBL] [Abstract][Full Text] [Related]
50. Selective targeting of KRAS-mutant cells by miR-126 through repression of multiple genes essential for the survival of KRAS-mutant cells.
Hara T; Jones MF; Subramanian M; Li XL; Ou O; Zhu Y; Yang Y; Wakefield LM; Hussain SP; Gaedcke J; Ried T; Luo J; Caplen NJ; Lal A
Oncotarget; 2014 Sep; 5(17):7635-50. PubMed ID: 25245095
[TBL] [Abstract][Full Text] [Related]
51. KRAS up-regulates the expression of miR-181a, miR-200c and miR-210 in a three-dimensional-specific manner in DLD-1 colorectal cancer cells.
Ota T; Doi K; Fujimoto T; Tanaka Y; Ogawa M; Matsuzaki H; Kuroki M; Miyamoto S; Shirasawa S; Tsunoda T
Anticancer Res; 2012 Jun; 32(6):2271-5. PubMed ID: 22641662
[TBL] [Abstract][Full Text] [Related]
52. p21-Activated kinase 1 is required for efficient tumor formation and progression in a Ras-mediated skin cancer model.
Chow HY; Jubb AM; Koch JN; Jaffer ZM; Stepanova D; Campbell DA; Duron SG; O'Farrell M; Cai KQ; Klein-Szanto AJ; Gutkind JS; Hoeflich KP; Chernoff J
Cancer Res; 2012 Nov; 72(22):5966-75. PubMed ID: 22983922
[TBL] [Abstract][Full Text] [Related]
53. Micro-RNAs miR-29a and miR-330-5p function as tumor suppressors by targeting the MUC1 mucin in pancreatic cancer cells.
Tréhoux S; Lahdaoui F; Delpu Y; Renaud F; Leteurtre E; Torrisani J; Jonckheere N; Van Seuningen I
Biochim Biophys Acta; 2015 Oct; 1853(10 Pt A):2392-403. PubMed ID: 26036346
[TBL] [Abstract][Full Text] [Related]
54. Sp1-driven up-regulation of miR-19a decreases RHOB and promotes pancreatic cancer.
Tan Y; Yin H; Zhang H; Fang J; Zheng W; Li D; Li Y; Cao W; Sun C; Liang Y; Zeng J; Zou H; Fu W; Yang X
Oncotarget; 2015 Jul; 6(19):17391-403. PubMed ID: 26041879
[TBL] [Abstract][Full Text] [Related]
55. In vivo serial selection of human pancreatic cancer cells in orthotopic mouse models produces high metastatic variants irrespective of Kras status.
Metildi CA; Kaushal S; Hoffman RM; Bouvet M
J Surg Res; 2013 Sep; 184(1):290-8. PubMed ID: 23590868
[TBL] [Abstract][Full Text] [Related]
56. Loss of EGFR signaling regulated miR-203 promotes prostate cancer bone metastasis and tyrosine kinase inhibitors resistance.
Siu MK; Abou-Kheir W; Yin JJ; Chang YS; Barrett B; Suau F; Casey O; Chen WY; Fang L; Hynes P; Hsieh YY; Liu YN; Huang J; Kelly K
Oncotarget; 2014 Jun; 5(11):3770-84. PubMed ID: 25004126
[TBL] [Abstract][Full Text] [Related]
57. Emerging role of the KRAS-PDK1 axis in pancreatic cancer.
Ferro R; Falasca M
World J Gastroenterol; 2014 Aug; 20(31):10752-7. PubMed ID: 25152578
[TBL] [Abstract][Full Text] [Related]
58. MAZ-binding G4-decoy with locked nucleic acid and twisted intercalating nucleic acid modifications suppresses KRAS in pancreatic cancer cells and delays tumor growth in mice.
Cogoi S; Zorzet S; Rapozzi V; Géci I; Pedersen EB; Xodo LE
Nucleic Acids Res; 2013 Apr; 41(7):4049-64. PubMed ID: 23471001
[TBL] [Abstract][Full Text] [Related]
59. MicroRNAs 143 and 145 may be involved in benign prostatic hyperplasia pathogenesis through regulation of target genes and proteins.
Viana NI; Reis ST; Dip NG; Morais DR; Moura CM; Silva IA; Katz B; Srougi M; Leite KR; Antunes AA
Int J Biol Markers; 2014 Sep; 29(3):e246-52. PubMed ID: 24474452
[TBL] [Abstract][Full Text] [Related]
60. Roles for KRAS in pancreatic tumor development and progression.
di Magliano MP; Logsdon CD
Gastroenterology; 2013 Jun; 144(6):1220-9. PubMed ID: 23622131
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
